中国抗击新型冠状病毒的策略与进展
发布时间：2022-01-20 16:14
新型冠状病毒肺炎（COVID-19）是21世纪第三次由冠状病毒引发的流行病,并导致全球大规模感染和死亡,造成全球性公共卫生事件。基于在防控重症急性呼吸综合征（SARS）和中东呼吸综合征（MERS）两次疫情中积累的经验,中国迅速确定病毒传播途径,总结临床特点,提出治疗干预措施并开展疫苗研发,在科学界发挥了关键作用。尽管针对COVID-19的研究取得了快速进展,但在追溯病毒起源、明确传播途径和解析致病机制等方面仍有待进一步研究。目前仍需建立更具针对性的临床治疗方案以及研发特效药。本文总结了中国针对COVID-19防控的主要策略及研究进展,以期为全球疫情防控提供有用的信息。
【文章来源】：Engineering. 2020,6(10)EISCI
【文章页数】：20 页
【文章目录】：
1. Introduction
2. Overview of the strategies for battling against COVID-19 in China
3. Possible mechanisms underlying viral infection
4. Transmission routes
5. Advances in laboratory diagnosis
6. Clinical characteristics of COVID-19
7. Prognostic prediction of critical illnesses
8. Advances in clinical management
9. Vaccine development
1 0. Summary
1.引言
2.中国抗击COVID-19的策略概述
3.SARS-Co V-2的感染机制
4.传播途径
5.实验室诊断的进展
6.COVID-19的临床特点
7.危重症患者的预后预测
8.临床治疗进展
9.疫苗研发
10.结语
【参考文献】：
期刊论文
[1]Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19[J]. Jing-Chun Song,Gang Wang,Wei Zhang,Yang Zhang,Wei-Qin Li,Zhou Zhou. Military Medical Research. 2020(04)
[2]Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19[J]. Mingxing Huang,Man Li,Fei Xiao,Pengfei Pang,Jiabi Liang,Tiantian Tang,Shaoxuan Liu,Binghui Chen,Jingxian Shu,Yingying You,Yang Li,Meiwen Tang,Jianhui Zhou,Guanmin Jiang,Jingfen Xiang,Wenxin Hong,Songmei He,Zhaoqin Wang,Jianhua Feng,Changqing Lin,Yinong Ye,Zhilong Wu,Yaocai Li,Bei Zhong,Ruilin Sun,Zhongsi Hong,Jing Liu,Huili Chen,Xiaohua Wang,Zhonghe Li,Duanqing Pei,Lin Tian,Jinyu Xia,Shanping Jiang,Nanshan Zhong,Hong Shan. National Science Review. 2020(09)
[3]基于CRISPR/Cas12a的可视荧光法快速灵敏检测新型冠状病毒（英文）[J]. 王鑫杰,钟名天,刘勇,马培祥,党露,孟庆洲,万闻蔚,马晓冬,刘佳,杨光,杨子峰,黄行许,刘明. Science Bulletin. 2020(17)
[4]血必净注射液对重型新型冠状病毒肺炎患者炎症指标及病情转归的疗效观察[J]. 文隆,周志国,姜迪譞,黄康. 中华危重病急救医学. 2020(04)
本文编号：3599136
【文章来源】：Engineering. 2020,6(10)EISCI
【文章页数】：20 页
【文章目录】：
1. Introduction
2. Overview of the strategies for battling against COVID-19 in China
3. Possible mechanisms underlying viral infection
4. Transmission routes
5. Advances in laboratory diagnosis
6. Clinical characteristics of COVID-19
7. Prognostic prediction of critical illnesses
8. Advances in clinical management
9. Vaccine development
1 0. Summary
1.引言
2.中国抗击COVID-19的策略概述
3.SARS-Co V-2的感染机制
4.传播途径
5.实验室诊断的进展
6.COVID-19的临床特点
7.危重症患者的预后预测
8.临床治疗进展
9.疫苗研发
10.结语
【参考文献】：
期刊论文
[1]Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19[J]. Jing-Chun Song,Gang Wang,Wei Zhang,Yang Zhang,Wei-Qin Li,Zhou Zhou. Military Medical Research. 2020(04)
[2]Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19[J]. Mingxing Huang,Man Li,Fei Xiao,Pengfei Pang,Jiabi Liang,Tiantian Tang,Shaoxuan Liu,Binghui Chen,Jingxian Shu,Yingying You,Yang Li,Meiwen Tang,Jianhui Zhou,Guanmin Jiang,Jingfen Xiang,Wenxin Hong,Songmei He,Zhaoqin Wang,Jianhua Feng,Changqing Lin,Yinong Ye,Zhilong Wu,Yaocai Li,Bei Zhong,Ruilin Sun,Zhongsi Hong,Jing Liu,Huili Chen,Xiaohua Wang,Zhonghe Li,Duanqing Pei,Lin Tian,Jinyu Xia,Shanping Jiang,Nanshan Zhong,Hong Shan. National Science Review. 2020(09)
[3]基于CRISPR/Cas12a的可视荧光法快速灵敏检测新型冠状病毒（英文）[J]. 王鑫杰,钟名天,刘勇,马培祥,党露,孟庆洲,万闻蔚,马晓冬,刘佳,杨光,杨子峰,黄行许,刘明. Science Bulletin. 2020(17)
[4]血必净注射液对重型新型冠状病毒肺炎患者炎症指标及病情转归的疗效观察[J]. 文隆,周志国,姜迪譞,黄康. 中华危重病急救医学. 2020(04)
本文编号：3599136
本文链接：https://www.wllwen.com/yixuelunwen/liuxingb/3599136.html
